Loading…
Are the original SARS‐CoV‐2 novel mutants from in vitro culture able to escape the immune response?
Monitoring variations in the virus genome to understand the SARS‐CoV‐2 evolution and spread of the virus is extremely important. Seven early SARS‐CoV‐2 isolates in China were cultured in vitro and were analyzed for their viral infectivity through viral growth assay, tissue culture infectious dose (T...
Saved in:
Published in: | Journal of medical virology 2023-07, Vol.95 (7), p.e28931-n/a |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Monitoring variations in the virus genome to understand the SARS‐CoV‐2 evolution and spread of the virus is extremely important. Seven early SARS‐CoV‐2 isolates in China were cultured in vitro and were analyzed for their viral infectivity through viral growth assay, tissue culture infectious dose (TCID50) assay, spike protein quantification, and next generation sequencing analysis, and the resultant mutations in spike protein were used to generate the corresponding pseudoviruses for analysis of immune escape from vaccination and postinfection immunity. The results revealed that in vitro cultured SARS‐CoV‐2 virus had much higher mutation frequency (up to ~20 times) than that in infected patients, suggesting that SARS‐CoV‐2 diversify under favorable conditions. Monitoring viral mutations is not only helpful for better understanding of virus evolution and virulence change, but also the key to prevent virus transmission and disease progression. Compared with the D614G reference strain, a pseudovirus strain of SARS‐CoV‐2 was constructed with a high mutation rate site on the spike protein. We found some novel spike mutations during in vitro culture, such as E868Q, conferred further immune escape ability. |
---|---|
ISSN: | 0146-6615 1096-9071 |
DOI: | 10.1002/jmv.28931 |